Compare CCNE & AGMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCNE | AGMB |
|---|---|---|
| Founded | 1865 | 2017 |
| Country | United States | Belgium |
| Employees | 950 | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 818.2M | 677.9M |
| IPO Year | N/A | N/A |
| Metric | CCNE | AGMB |
|---|---|---|
| Price | $30.20 | $11.65 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $34.50 | $32.00 |
| AVG Volume (30 Days) | 115.7K | ★ 137.3K |
| Earning Date | 04-20-2026 | 04-23-2026 |
| Dividend Yield | ★ 2.51% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.21 | N/A |
| Revenue Next Year | $7.00 | $17.86 |
| P/E Ratio | $11.84 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $21.19 | $9.00 |
| 52 Week High | $31.80 | $17.45 |
| Indicator | CCNE | AGMB |
|---|---|---|
| Relative Strength Index (RSI) | 50.61 | 54.88 |
| Support Level | $29.64 | $10.30 |
| Resistance Level | $30.57 | $12.21 |
| Average True Range (ATR) | 0.80 | 0.84 |
| MACD | -0.12 | 0.21 |
| Stochastic Oscillator | 24.54 | 68.15 |
CNB Financial Corp is a Pennsylvania-chartered bank. The bank is a full-service bank engaging in a full range of banking activities and services for individual, business, governmental and institutional customers. These activities and services principally include checking, savings, and time deposit accounts; real estate, commercial, industrial, residential and consumer loans; and a variety of other specialized financial services. Its Private Client Solutions division offers a full range of client services, including private banking and wealth and asset management. The banking segment derives its revenue through the operations as a full-service bank services, including trust and wealth management services, for individual, business, governmental, and institutional customers.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.